2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107398
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride 39959-66-5 99.93%
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride is a phenylethanolamine N-methyltransferase (PNMT) inhibitor. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride effectively reduces blood pressure of spontaneously hypertensive. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride can be used for the research of blood pressure.
    1-(2,3-Dichlorophenyl)ethanamine hydrochloride
  • HY-124370
    9(Z),11(E)-Conjugated linoleic acid methyl ester 13058-52-1 ≥99.0%
    9(Z),11(E)-Conjugated linoleic acid methyl ester (9Z,11E-CLA; Methyl 9(Z),11(E)-octadecadienoate; (9Z,11E)-SFE 19:2) is an isomer of Linoleic acid (HY-N0729). Conjugated linoleic acid is a bioactive fatty acid, which can improve body composition, enhance immune system function, exhibits anti-cancer and antiatherosclerosis effect.
    9(Z),11(E)-Conjugated linoleic acid methyl ester
  • HY-15477A
    YS-49 monohydrate 3028631-24-2 99.56%
    YS-49 (monohydrate) is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors.
    YS-49 monohydrate
  • HY-B0428A
    Ozagrel sodium 189224-26-8 99.98%
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
    Ozagrel sodium
  • HY-N0666R
    L-Aspartic acid (Standard) 56-84-8
    L-Aspartic acid (Standard) is the analytical standard of L-Aspartic acid. This product is intended for research and analytical applications. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
    L-Aspartic acid (Standard)
  • HY-N1214R
    Squalene (Standard) 111-02-4
    Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity.
    Squalene (Standard)
  • HY-P10554
    Myhc-α(334–352) 171675-09-5 99.67%
    Myhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiac myosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) can be used to study the autoimmune pathways of myocarditis and dilated cardiomyopathy.
    Myhc-α(334–352)
  • HY-U00137
    YS-201 108852-42-2 ≥99.0%
    YS-201 is a dihydropyridine-type calcium channel antagonist. YS-201 has the potential for angina pectoris and hypertension treatment.
    YS-201
  • HY-U00398
    Bimoclomol 130493-03-7 99.29%
    Bimoclomol is a heat shock protein (HSP) coinducer, used for treatment of cardiovascular diseases.
    Bimoclomol
  • HY-113466S
    4-Hydroxynonenal-d3 148706-06-3 ≥99.0%
    4-Hydroxynonenal-d3 is the deuterium labeled 4-Hydroxynonenal. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria[1][2][3].
    4-Hydroxynonenal-d3
  • HY-P1033S1
    [Pyr1]-Apelin-13, Pro(13C5,15N) TFA 99.85%
    [Pyr1]-Apelin-13, Pro(13C5,15N) (TFA) is the 13C and 15N labeled isotope of [Pyr1]-Apelin-13(HY-P1033).[Pyr1]-Apelin-13 is a potent and selective endogenous apelin receptor agonist.
    [Pyr1]-Apelin-13, Pro(13C5,15N) TFA
  • HY-P10641A
    Heart-homing peptide TFA
    Heart-homing peptide TFA is a Pentapeptide, CRPPR. CRPPR is a linear peptide containing arginine that has been identified as a heart-homing peptide owing to its ability to specifically bind to heart endothelium, and cysteine-rich protein-2 (CRIP-2) has been proposed as the receptor. Heart-homing peptide TFA can be used for conjugating liposomes.
    Heart-homing peptide TFA
  • HY-10195A
    Ruboxistaurin mesylate 192050-59-2 99.87%
    Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes.
    Ruboxistaurin mesylate
  • HY-101028
    ZINC13466751 117953-17-0 99.94%
    ZINC13466751 is a potent inhibitor of HIF-1α/von Hippel-Lindau interaction with an IC50 of 2.0 µM.
    ZINC13466751
  • HY-107744
    Nalmefene 55096-26-9 99.70%
    Nalmefene is a BBB-penatrable opioid receptor modulator. Nalmefene is an antagonist of MOR and DOR, and a partial agonist of KOR. Nalmefene has anti-inflammatory and neuroprotective activities. Nalmefene can be used in the research of reducing alcohol-dependent disorders.
    Nalmefene
  • HY-162897
    BAY-2413555 2206665-50-9
    BAY-2413555 is an orally active muscarinic acetylcholine receptor M2 modulator that protects the heart and improve cardiac function. BAY-2413555 is promising for research of heart failure.
    BAY-2413555
  • HY-P5127
    CNP-38 99.63%
    CNP-38 is a C-type natriuretic peptide.
    CNP-38
  • HY-106281
    Bemfivastatin 805241-79-6 99.48%
    Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins.
    Bemfivastatin
  • HY-107867
    (±)-Clopidogrel bisulfate 135046-48-9 99.97%
    (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects.
    (±)-Clopidogrel bisulfate
  • HY-108798
    Ziv-aflibercept 1609655-49-3
    Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases.
    Ziv-aflibercept
Cat. No. Product Name / Synonyms Application Reactivity